Inactive Instrument

Microbot Medical Inc Stock Nasdaq

Equities

US59503A1051

Biotechnology & Medical Research

Sales 2024 * - Sales 2025 * - Capitalization 14.83M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.32%
More Fundamentals * Assessed data
Dynamic Chart
Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Microbot Medical Submits US FDA Application to Start Human Clinical Trial for Robotic Surgical System MT
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US CI
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study CI
Sector Update: Health Care Stocks Ease Friday Afternoon MT
Microbot Medical to Exercise Outstanding Preferred Investment Options for $2.7 Million MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met CI
Microbot Medical Says GLP Preclinical Study of Liberty Endovascular Robotic Surgical System Met Objectives; Shares Rise MT
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY Endovascular Robotic Surgical System for Telerobotic CI
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study CI
Microbot Medical Inc. Announces Executive Changes CI
Microbot Medical Files $75 Million Shelf MT
Microbot Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 52 88-08-01
Director of Finance/CFO 45 21-12-31
Chief Tech/Sci/R&D Officer - Nov. 30
Members of the board TitleAgeSince
Director/Board Member 59 16-11-27
Director/Board Member 66 17-12-11
Director/Board Member 50 20-07-31
More insiders
Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
More about the company